Add BrightSurf on Google Email

Science News for October 10, 2010


Cetuximab did not add significant benefit to NORDIC FLOX regimen in first line treatment of mCRC

Researchers reported that adding cetuximab to a three-drug chemotherapy regimen for first-line treatment of metastatic colorectal cancer did not improve response rates, progression-free survival, or overall survival. The NORDIC VII study included 566 patients and found no statistically significant differences between the treatment groups.

SourceEuropean Society for Medical Oncology·JournalAnnals of Oncology·DateOct 10, 2010

Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer

In a phase II study, patients with locally advanced and metastatic NSCLC experienced significant increases in survival time when treated with TTF therapy in combination with chemotherapy. The therapy has also been shown to have clinical efficacy in human trials for other solid tumors, including recurrent glioblastoma.

Struggling for breath

Researchers found that patients with pectus excavatum have reduced chest wall motion near the deformity and compensate by using abdominal muscles to draw in more air. The study suggests these patients may experience shortness of breath and easy fatigability due to the dysfunctional upper chest wall motion.

Prolonging first-line chemotherapy improves outcomes for patients with metastatic breast cancer

A new meta-analysis shows that continuing chemotherapy after bringing cancer under control can increase survival time and reduce disease progression in metastatic breast cancer patients. The analysis found a 34% reduction in disease progression and a 9% reduction in death rates for patients who received longer chemotherapy durations.

SourceEuropean Society for Medical Oncology·JournalAnnals of Oncology·DateOct 10, 2010

New definition of Alzheimer's disease could help select patients for trials of disease-modifying treatments

A new definition of Alzheimer's disease has been proposed to diagnose the condition earlier and select patients for trials of disease-modifying treatments. The revised definition includes biomarkers as a key diagnostic feature, enabling diagnosis at an earlier stage, and allows for more precise selection of patients for clinical trials.

SourceThe Lancet_DELETED·JournalThe Lancet Neurology·DateOct 10, 2010